tetano
Editor, Senior Moderator
Clin Immunol Commun
. 2023 Dec:3:1-5.
doi: 10.1016/j.clicom.2022.12.001. Epub 2022 Dec 11. Partial recovery of SARS-CoV-2 immunity after booster vaccination in renal transplant recipients
J M Urra[SUP] 1 2 [/SUP], P Castro[SUP] 3 [/SUP], N Jiménez[SUP] 1 [/SUP], E Moral[SUP] 3 [/SUP], C Vozmediano[SUP] 2 3 [/SUP]
Affiliations
The pandemic caused by the SARS-CoV-2 coronavirus has been especially detrimental to patients with end-stage renal disease. History with other vaccines suggests that patients with renal disease may not respond adequately to the SARS-CoV-2 vaccine. The aim of this study is to evaluate the immunity to SARS-CoV-2 mRNA vaccines in renal patients. Post SARS-CoV-2 vaccination first, and after the booster dose, antibodies and cellular immunity were studied in patients on hemodialysis (N = 20), peritoneal dialysis (N = 10) and renal transplantation (N = 10). After the two doses of vaccine, there was an effective immunity in dialysis patients, with 100% seroconversion and 87% detection of cellular immunity (85% in hemodialysis and 90% in peritoneal dialysis). In contrast, in renal transplant recipients there was only 50% seroconversion and cellular immunity was detected in 30% of patients. After the booster dose, all dialysis patients achieved a cellular and antibody immunity, whereas in transplant patients, despite improvement, 20% did not produce antibodies and in 37.5% cellular immunity could not be detected. The mRNA vaccine plus booster performs excellently in dialysis patients, whereas in kidney transplant recipients, despite the booster, complete immunization is not achieved.
Keywords: End stage kidney disease; Hemodialysis; Peritoneal dialysis; Renal transplant recipient; SARS-CoV-2 vaccine.
. 2023 Dec:3:1-5.
doi: 10.1016/j.clicom.2022.12.001. Epub 2022 Dec 11. Partial recovery of SARS-CoV-2 immunity after booster vaccination in renal transplant recipients
J M Urra[SUP] 1 2 [/SUP], P Castro[SUP] 3 [/SUP], N Jiménez[SUP] 1 [/SUP], E Moral[SUP] 3 [/SUP], C Vozmediano[SUP] 2 3 [/SUP]
Affiliations
- PMID: 38014395
- PMCID: PMC9741556
- DOI: 10.1016/j.clicom.2022.12.001
The pandemic caused by the SARS-CoV-2 coronavirus has been especially detrimental to patients with end-stage renal disease. History with other vaccines suggests that patients with renal disease may not respond adequately to the SARS-CoV-2 vaccine. The aim of this study is to evaluate the immunity to SARS-CoV-2 mRNA vaccines in renal patients. Post SARS-CoV-2 vaccination first, and after the booster dose, antibodies and cellular immunity were studied in patients on hemodialysis (N = 20), peritoneal dialysis (N = 10) and renal transplantation (N = 10). After the two doses of vaccine, there was an effective immunity in dialysis patients, with 100% seroconversion and 87% detection of cellular immunity (85% in hemodialysis and 90% in peritoneal dialysis). In contrast, in renal transplant recipients there was only 50% seroconversion and cellular immunity was detected in 30% of patients. After the booster dose, all dialysis patients achieved a cellular and antibody immunity, whereas in transplant patients, despite improvement, 20% did not produce antibodies and in 37.5% cellular immunity could not be detected. The mRNA vaccine plus booster performs excellently in dialysis patients, whereas in kidney transplant recipients, despite the booster, complete immunization is not achieved.
Keywords: End stage kidney disease; Hemodialysis; Peritoneal dialysis; Renal transplant recipient; SARS-CoV-2 vaccine.